"We are still moving both forward in the clinic and exploring optimal development and funding paths for these assets." For the latest quarter, 23andMe reported total revenue of $40 million, down 34% from its revenue of $61 million during the same period a year ago
GLP-1 drug shows little benefit for people with Parkinsons disease 5 February 2025 The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinsons disease, finds a new study led by UCL researchers
Reputable suppliers report both
April 24, 2026 BPC-157 delivery routes research covering subcutaneous, intramuscular, oral, and other administration routes, pharmacokinetic profiles, and tissue distribution in animal research models
Diabetes Spend Is Growing 4 Slower Than Non-Diabetic Costs: What the Data Shows The financial data shows an unmistakable shift: Annual spend for diabetics increased just 11% from 2021-2024 , while spend for non-diabetics jumped 15% Average monthly medical spend for diabetics decreased slightly (0.5%) , while non-diabetic medical spend surged 17% Prescription growth for diabetics (34%) stayed well below the 57% spike for non-diabetics For the first time, diabetic spend is flattening faster than non-diabetic spendcompletely reversing the previous pattern where diabetes costs outpaced everything else by 2x
00371-1/asset/b72639d6-69a5-4ae0-81c1-18ceb79be753/main.assets/gr2_lrg.jpg)
